MORRISVILLE, N.C. and PALO ALTO, Calif., Jan. 30 /PRNewswire/ -- Diagnosoft, Inc., an innovator in magnetic resonance (MR) image analysis software that assists in diagnosis, staging and therapeutic monitoring of cardiovascular disease, has unveiled its newest software solution: Diagnosoft(R) SENC. Strain-encoding, or SENC, is a new MRI analysis technique that will help physicians measure regional contraction, or relaxation, of the heart’s myocardium. Like Diagnosoft’s other two software products, Diagnosoft(R) HARP(TM) and Diagnosoft(R) PLUS, Diagnosoft(R) SENC enables quantification of data to improve diagnosis and guide monitoring and treatment of coronary artery disease.
Developed by Dr. Nael Osman, a faculty member at Johns Hopkins University, SENC is now a proprietary product of Diagnosoft, Inc. According to Dr. Osman, co-founder of Diagnosoft, “Diagnosoft(R) SENC provides an objective way to assess regional variations in muscle contraction due to ischemia, myocardial infarction, or other causes. Moreover, Diagnosoft(R) SENC produces maps of regional function with high spatial resolution at a level of quality sufficient even for the thin wall of the right ventricle. As a result, the technique can reveal small regional anomalies in contractility within the wall.”
Most cardiac MRI procedures require patients to hold their breath. However, SENC images can be acquired in a fraction of a second, mapping regional function with unprecedented speed, so it can be used in combination with tests and maneuvers that allow patients to breathe normally. That means SENC is suitable for stress testing of cardiac function, as well as other diagnostic tests.
Dr. Osman said new Diagnosoft(R) SENC is a great addition to a rich and unique product suite originated with Diagnosoft(R) HARP(TM), “While MR tagged images can be produced on most MRI systems, this pulse sequence has limited spatial resolution and takes time to acquire. SENC pulse sequence does not require a second step of image processing, as does analyzing tagged MR images, so it streamlines throughput and decision-making.”
About Diagnosoft
Diagnosoft, Inc., based in North Carolina and California, is a privately held company specializing in image analysis software that assists in diagnosis, staging and therapeutic monitoring of cardiovascular disease. One of its products, Diagnosoft HARP(TM), is distinguished as the first FDA 510k-cleared software designed for the analysis of tagged magnetic resonance images. The company is focused on improving physician workflow, quantifying decision-making, and enhancing research and drug development advances.
Company founders Dr. Nael Osman and Dr. Jerry Prince, developed HARP technology at Johns Hopkins University (JHU), where they are faculty members. Dr. Matthias Stuber, a company founder who is also on the JHU faculty, brings additional insight and imaging expertise to Diagnosoft. More information about the company’s three MRI analysis software products, Diagnosoft(R) HARP(TM), Diagnosoft(R) Plus and new Diagnosoft(R) SENC, is available at www.diagnosoft.com.
Diagnosoft(R) is a registered trademark of Diagnosoft, Inc. HARP(R) is a registered trademark of Johns Hopkins University. Diagnosoft, Inc. disclaims any proprietary interest in the marks and names of others.
CONTACT: Firas BenAchour of Diagnosoft, Inc., +1-919-388-9492
Web site: http://www.diagnosoft.com/
